Lonza Completes Acquisition of Capsugel
Lonza announced that following the receipt of all required regulatory approvals, it has completed the acquisition of Capsugel S.A. (“Capsugel”) from KKR for USD 5.5 billion in cash, including refinancing of existing Capsugel debt of approximately USD 2 billion. The acquisition of Capsugel is expected to be accretive to Lonza’s core earnings per share in the first full year post closing.
This acquisition is in line with Lonza’s stated strategy to accelerate growth and deliver value along the healthcare continuum by complementing its existing offerings and by opening up new market opportunities in the pharma and consumer healthcare and nutrition industries.
With the acquisition of Capsugel, Lonza adds a trusted brand with a large breadth of technologies that it believes will expand the market reach of both companies’ contract development and manufacturing organization (CDMO) and products businesses. It also supports Lonza’s strategic ambition of getting closer to the patient and end consumer.
Richard Ridinger, Lonza's Chief Executive Officer, said, “Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration.”
Capsugel’s business will continue to operate in its existing structure until the full integration has been completed.
The acquisition was financed partially through the net proceeds of the successful placement of 5 million new shares at CHF 173.00 per share with total gross proceeds of CHF 865 million, which was completed in February 2017, as well as the issuance of 16,548,612 fully paid registered shares, with gross proceeds in the amount of CHF 2.26 billion, which was completed in May 2017. The balance of the acquisition price was financed through indebtedness.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
BioHyTec - Verein für Bioanalytik und Biohybrid-Technologien e.V. - Nuthetal, Germany
Arakis commences Phase IIB trial for rheumatoid arthritis drug
Why Doesn’t Honey Spoil?
Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary
Ablynx announces cancer immunotherapy discovery collaboration with Merck
Category:Vascular_surgery
Study finds breast and ovarian cancer may have similar origins
Evonik ends cooperation with Chr. Hansen
Category:Female_sexual_dysfunction_drugs
Frederick W. Alt and David G. Schatz to be awarded the 2023 Paul Ehrlich and Ludwig Darmstaedter Prize - Laureates raised knowledge of the development of the immune system to a new level
Chemotherapy timing is key to success - Nanoparticles that stagger delivery of 2 drugs knock out aggressive tumors in mice
